Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DURABLE study of biphasic insulin lispro versus insulin glargine in type 2 diabetes
2005-004963-42Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of insulin lispro and insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Initial phase safety and efficacy comparison, Durability of glycemic control over 30 months and 4 more. Started Dec 2005; status: completed.
02
Drugs
insulin lisproinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2005-004963-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004963-42.